Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials, such as cells, proteins, and nucleic acids used in biopharmaceutical manufacturing, quality control process, food safety, and science education applications. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, and transfusion and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Bio-Rad Laboratories Inc. Class A

Healthcare stocks are in focus this month as investors look for steady growth and clear catalysts in a market dealing with volatility and uneven se...

3 Best Healthcare Stocks to Buy in June, According to Analysts

BioAge Labs, Inc. ($BIOA) announced an update on their ongoing clinical study. BioAge Labs, Inc. has launched a Phase 2 trial titled “A Phase 2, Ra...

BioAge Moves BGE-102 Into Mid-Stage Obesity Heart-Risk Trial, Raising New Investor Focus

An update from Valion Bio ( ($VBIO) ) is now available. On June 17, 2026, Valion Bio, Inc. issued 250 shares of its Series B Non-Voting Convertible...

Valion Bio Completes New Preferred Stock Financing Round

BTIG analyst maintained a Hold rating on Orchestra BioMed Holdings on June 15. The company’s shares closed yesterday at $3.97. Currently, the analy...

Orchestra BioMed Holdings (OBIO) Gets a Hold from BTIG

Analysts have been eager to weigh in on the Healthcare sector with new ratings on IQVIA Holdings (IQV), BridgeBio Pharma (BBIO) and Guardant Health...

Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), BridgeBio Pharma (BBIO) and Guardant Health (GH)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alto Neuroscience, Inc. (ANRO) and BridgeBio Pharma ...

Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO) and BridgeBio Pharma (BBIO)

The latest update is out from BB Biotech ( ($CH:BION) ). BB Biotech AG has announced an updated total number of voting rights, confirming that as o...

BB Biotech Updates Total Voting Rights Following Capital Measure

The latest announcement is out from BioAge Labs, Inc. ( ($BIOA) ). On June 10, 2026, BioAge Labs, Inc. stockholders elected three Class II director...

BioAge Labs Shareholders Reelect Directors, Ratify Auditor

Jade Biosciences ( ($JBIO) ) has provided an announcement. Jade Biosciences, Inc. held its 2026 Annual Meeting of Stockholders on June 9, 2026, whe...

Jade Biosciences Shareholders Approve Governance and Audit Measures

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Alpha Cognition Inc (ACOG), Zenas BioPharma, Inc. (Z...

Analysts Are Bullish on Top Healthcare Stocks: Alpha Cognition Inc (ACOG), Zenas BioPharma, Inc. (ZBIO)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Olema Pharmaceuticals (OLMA), Jade Biosciences (JBIO...

Analysts Offer Insights on Healthcare Companies: Olema Pharmaceuticals (OLMA), Jade Biosciences (JBIO) and Oculis Holding (OCS)

Analysts are intrested in these 5 stocks: ( ($LDOS) ), ( ($BBIO) ), ( ($TE) ), ( ($EC) ) and ( ($MDT) ). Here is a breakdown of their recent


Leidos, BridgeBio, T1 Energy, Ecopetrol, Medtronic Trending

Analysts are intrested in these 5 stocks: ( ($CPB) ), ( ($CBIO) ), ( ($CRDF) ), ( ($SHW) ) and ( ($TTWO) ). Here is a breakdown of their recent


Campbell, Crescent, Cardiff, Sherwin, Take-Two Trending With Analysts

In a report released today, Eliana Merle from Barclays maintained a Buy rating on BridgeBio Pharma, with a price target of $157.00. Merle covers th...

Barclays Sticks to Their Buy Rating for BridgeBio Pharma (BBIO)

Jade Biosciences ( ($JBIO) ) just unveiled an update. On June 3, 2026, Jade Biosciences, Inc. entered into an underwriting agreement with a syndica...

Jade Biosciences Launches Major Underwritten Equity Offering

Jade Biosciences, Inc. ($JBIO) announced an update on their ongoing clinical study. Jade Biosciences, Inc. has launched a Phase 1 trial called “A S...

JADE101 Phase 1 Trial Marks Key Early Milestone for Jade Biosciences Investors

Valion Bio ( ($VBIO) ) has shared an announcement. On May 28, 2026, Valion Bio held its annual meeting virtually, with 50% of the 3,139,095 outstan...

Valion Bio Shareholders Approve Director, Auditor and Equity Plan

Crescent Biopharma ( ($CBIO) ) just unveiled an update. On June 2, 2026, Crescent Biopharma, Inc. held its annual general meeting of shareholders, ...

Crescent Biopharma shareholders back directors, pay and auditor

Harvard Bioscience ( ($HBIO) ) has issued an update. On June 2, 2026, Harvard Bioscience stockholders approved an amendment to the 2021 Incentive P...

Harvard Bioscience Shareholders Expand Equity Plans, Elect Directors

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Foghorn Therapeutics (FHTX) and Jade Biosciences (JB...

Analysts Offer Insights on Healthcare Companies: Foghorn Therapeutics (FHTX) and Jade Biosciences (JBIO)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aligos Therapeutics (ALGS) and Jade Biosciences (JBI...

Analysts Are Bullish on Top Healthcare Stocks: Aligos Therapeutics (ALGS), Jade Biosciences (JBIO)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Crescent Biopharma (CBIO) and IQVIA Holdings (IQV) w...

Analysts Are Bullish on These Healthcare Stocks: Crescent Biopharma (CBIO), IQVIA Holdings (IQV)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Tempus AI, Inc. Class A (TEM), Tyra Bioscience (TY...

Analysts Conflicted on These Healthcare Names: Tempus AI, Inc. Class A (TEM), Tyra Bioscience (TYRA) and BridgeBio Pharma (BBIO)

Analysts are intrested in these 5 stocks: ( ($BBIO) ), ( ($DAVE) ), ( ($MRVL) ), ( ($FLNA) ) and ( ($GE) ). Here is a breakdown of their recent


BridgeBio, Dave, Marvell, Filana, GE Trending With Analysts

Ibio Inc ($IBIO) announced an update on their ongoing clinical study. The Phase 1 IBIO-600-CT001 study aims to test a new obesity drug in adults wi...

IBIO-600 First-in-Human Obesity Trial Puts iBio on Investors’ Radar

Jade Biosciences, Inc. ($JBIO) announced an update on their ongoing clinical study. The Phase 2 JUNIPER study from Jade Biosciences, Inc. focuses o...

Jade Biosciences’ JADE101 Trial Opens a New Front in IgA Nephropathy Investing

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Bristol-Myers Squibb (BMY) and BridgeBio Pharma (BBI...

Analysts Are Bullish on These Healthcare Stocks: Bristol-Myers Squibb (BMY), BridgeBio Pharma (BBIO)

Biome Australia Ltd ( ($AU:BIO) ) has shared an announcement. Biome Australia has launched a multi-centre, randomised, double-blind, placebo-contro...

Biome Australia starts international multi-centre trial for first proprietary probiotic strain

The latest announcement is out from Biome Australia Ltd ( ($AU:BIO) ). Biome Australia will host a 30-minute investor webinar on 5 June 2026 to out...

Biome Australia to spotlight BMB18 clinical program and IP strategy in June investor webinar

An announcement from Swedish Orphan Biovitrum AB ( ($SE:SOBI) ) is now available. Sobi reported new pooled Phase 3 data showing that its RNA-target...

Sobi’s Tryngolza cuts pancreatitis risk 85% in severe hypertriglyceridemia trial analysis

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bio-Rad Laboratories (BIO) and Haleon PLC Sponsore...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BIO	$282.44	-0.78%	402.77K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BIO	$282.44	-0.8%	402.77K
3
4
5
6

BIO

BIO

Get Bio-Rad Laboratories Inc. Class A Data in Excel

Get Bio-Rad Laboratories Inc. Class A Data in Excel